Sign in
ENGN Stock Price, Chart, Stats & News
enGene Holdings Inc.
Save
87.27M
Market cap
–
Current P/E
–
Forward P/E
ENGN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 0.01% |
ROA | -36.32% |
ROE | -55.83% |
D/E | 0.12x |
Interest coverage ratio | -42.95x |
ENGN valuation
P/E | – |
P/S | – |
P/B | 1.52x |
P/CF | -4.18x |
P/FCF | -3.14x |
P/OCF | -4.18x |
PEG | -1.12x |
EV multiple | -2.77x |
About
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid.
Similar securities
Based on sector and market capitalization
Report issue